Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02154529
Title Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
Recruitment Terminated
Gender female
Phase Phase Ib/II
Variant Requirements No
Sponsors Kadmon Corporation, LLC

Her2-receptor positive breast cancer


Tesevatinib + Trastuzumab

Age Groups: adult
Covered Countries USA

No variant requirements are available.